. In addition, some of these tumours produce ligands for the receptor and it has been suggested that an autocrine mechanism is involved in progression of cancers of this type (Sporn & Roberts 1985; Imanishi et al., 1988; Nistar et al., 1988; Dernyck 1990; Tateishi et al., 1990; Yoshida et al., 1990; Morishige et al., 1991). Over-expression of the EGFR by tumour cells, compared to their normal counterparts, has been reported for a number of squamous cell carcinomas (e.g. Cowley et Hendler et al., 1984; Sainsbury et al., 1985; Gullick et al., 1986 ) and this in turn was also correlated to poor prognosis in patients with some of these carcinomas (reviewed by Gullick, 1991 We have reported (Modjtahedi, et al., 1992) the preparation and properties of ten rat mAbs that bind to three distinct epitopes (A,B,C) on the external domain of the EGFR using as immunogen the human squamous cell carcinoma HN5. While all of the mAbs against epitopes B and C blocked the binding of EGF and TGFa to the receptor on a number of squamous carcinoma cell lines the antibodies against epitope C were an order of magnitude better than the others at inhibiting cell growth. The best antibody, ICR16, inhibited completely the growth of HN5 cells in vitro at antibody concentrations above 1 nM. However, none of the antibodies was of the IgG2b isotype and therefore would not be expected to interact efficiently with the host immune effector functions in rat, mouse or man. Since our intention is to test the effectiveness of antibodies in the clinic we report here the preparation of a second series of antibodies using as immunogen the EGFR over-expressing breast carcinoma (Filmus et al., 1985) searching particularly for IgG2b antibodies with growth inhibitory properties. 
and are investigating their use for diagnostic and therapeutic applications in cancer patients whose tumours overexpress these receptors. The mAbs (three IgG2b and one each of IgG2a, IgGI and IgA) were selected on the basis that they bound to the extracellular domain of the EGFR and blocked growth factor-receptor interaction. Competitive assays showed that, with the exception of antibody ICR65, the mAbs bound to one of two distinct epitopes on the external domain of the EGFR. ICR65, however, cross-reacted with mAbs binding to both epitopes. All of the mAbs immunoprecipitated the 170 kDa glycoprotein from cells expressing the EGFR but not the 185 kDa product of the related c-erbB-2 proto-oncogene. Unlike EGF and TGFa none of the mAbs stimulated the growth of quiescent human foreskin fibroblasts but they inhibited the EGF and TGFa induced growth stimulation of these cells in vitro. When tested for their effect on tumour cells the mAbs were found to inhibit the growth in vitro of a number of human tumours that overexpressed the EGFR (e.g. HN5, HN6, HN15, A431, MDA-MB 468) but they were without effect on tumour cell lines expressing low or undetectable amounts of the receptor. Our initial results indicate that this new generation of antibodies which bind with high affinity to the EGFR, block growth factor-receptor interaction and inhibit the growth of human squamous carcinoma cell lines overexpressing the receptor have potential for clinical application.
Data from a number of laboratories indicate that overexpression of the receptor (EGFR) to which EGF, TGFa and other polypeptide hormones bind, plays an important role in the development of certain types of human malignancies (Santon et al., 1986; Ozanne et al., 1986; Velu et al., 1987; Difore et al., 1987; Harris et al., 1990) . In addition, some of these tumours produce ligands for the receptor and it has been suggested that an autocrine mechanism is involved in progression of cancers of this type (Sporn & Roberts 1985; Imanishi et al., 1988; Nistar et al., 1988; Dernyck 1990; Tateishi et al., 1990; Yoshida et al., 1990; Morishige et al., 1991) . Over-expression of the EGFR by tumour cells, compared to their normal counterparts, has been reported for a number of squamous cell carcinomas (e.g. Cowley et al., 1984; Hendler et al., 1984; Sainsbury et al., 1985; Gullick et al., 1986 ) and this in turn was also correlated to poor prognosis in patients with some of these carcinomas (reviewed by Gullick, 1991) .
The high level of expression of the EGFR on squamous cell carcinomas and the important role of the receptor (a 170 kD transmembrane tyrosine kinase) in signal transduction (Ullrich & Schlessinger, 1990) make it potentially an excellent target for antibody directed therapy (Mendelsohn, 1989) . Ideally, the antibody of choice would have the ability first to inhibit cell growth by blocking growth factor-receptor interaction and second to activate complement and recruit host effector cells to bring about tumour cell destruction.
Although a number of mouse monoclonal antibodies (mAbs) have been developed in the last decade using the A431 cell receptor as immunogen (e.g. Schreiber et al., 1981; Waterfield et al., 1982; Sato et al., 1983; Livneh et al., 1986; Murthy et al., 1987; Fendly et al., 1990; Pellegrini et al., 1991 ) only a few have either of the desired properties. Mouse antibodies are less effective in activating human effector functions than are rat antibodies of the IgG2b isotype (Hale et al., 1985; Dyer et al., 1989) . Furthermore, the effectiveness of monoclonal antibodies in harnessing host effector functions depends not only on the isotype of the antibody but also, importantly, on the particular epitope bound on the target antigen. For this reason it is necessary to search for an antibody that maximises the biological and immunological functions.
We have reported (Modjtahedi, et al., 1992 ) the preparation and properties of ten rat mAbs that bind to three distinct epitopes (A,B,C) on the external domain of the EGFR using as immunogen the human squamous cell carcinoma HN5. While all of the mAbs against epitopes B and C blocked the binding of EGF and TGFa to the receptor on a number of squamous carcinoma cell lines the antibodies against epitope C were an order of magnitude better than the others at inhibiting cell growth. The best antibody, ICR16, inhibited completely the growth of HN5 cells in vitro at antibody concentrations above 1 nM. However, none of the antibodies was of the IgG2b isotype and therefore would not be expected to interact efficiently with the host immune effector functions in rat, mouse or man. Since our intention is to test the effectiveness of antibodies in the clinic we report here the preparation of a second series of antibodies using as immunogen the EGFR over-expressing breast carcinoma (Filmus et al., 1985) searching particularly for IgG2b antibodies with growth inhibitory properties. (Styles et al., 1990) .
Control antibodies used in this investigation
MAb ALN/1 1/53 is directed against a membrane antigen on the rat sarcoma HSN (Dean et al., 1984) , ICR12 (Styles et al., 1990) and ICR55 are directed against distinct epitopes on the extracellular domain of the c-erbB-2 p185. Antibodies ICRIO and ICR16, prepared against the receptor on HN5 cells (Modjtahedi et al., 1992) , were used as positive controls. (1992) . Immunoreactivity, i.e. the proportion of radiolabelled antibody that would bind antigen at infinite antigen excess, was determined using a protocol similar to that described by Lindmo et al. (1984) .
Immunoprecipitation of 35S-methionine-labelled proteins
The proteins of HN5, SKOV3 or A431 cells were radiolabelled by incubation for 16-20 h with 35S-methionine (200 pCi/80 ml-1 flask containing 5 ml methionine-free DMEM), and cell lysates were prepared using Triton-X 100 as described previously (Styles et al., 1990 Effect of antibodies to the EGFR on growth of tumour cells in culture About 5 x 103 cells in 100 j4 of DMEM containing 2% FCS were seeded into each well of a 96-well plate. After incubation for 4 h at 37°C, 100 ftl aliquots of dilutions of each mAb (starting at 50 gLg ml) were added in triplicate to the wells and the cultures were incubated at 37°C. Controls were set up that contained either medium alone or medium containing dilutions of a control antibody (ALN/1 1/53). The cultures were incubated for a further 3 to 10 days until the controls incubated in medium alone were almost confluent and had increased in number to a maximum of 5 x I04 cells per well. All cells were fixed with 0.25% glutaraldehyde then washed in water, air dried and stained with 0.5% methylene blue (100 tll/well) for 15 min. After washing with tap water and air drying, 200 tL of 0.33N HCI was added to each well and the A620 of each supernatant was determined in a Titertek Multiscan. To determine the initial number of cells present at the start of treatment in each experiment, an extra plate was set up and the cells were fixed 4 h after the start of incubation at 37°C. Growth as a percent of control was determined from the formula:-% growth = B-A x 100 C-A Where A = A620 at start of experiment B = A620 after treatment with antibody C = A620 after incubation in medium alone
To investigate the effect of endogenous growth factors present in FCS on the activity of the antibodies, experiments were carried out using DMEM containing 2%, 5% or 10% FCS. Figure 1 . Three of these antibodies (ICR61, ICR62 and ICR65) were of the IgG2b isotype (Table I) . Competitive assays showed (Table II) (Table I) . ICR65, however, competed with all the new antibodies ( Figure 2 ) for binding to the receptor suggesting that epitopes C and D were adjacent. The immunoreactivity of the antibodies tested varied from 31% (ICR61) to 74% (ICR64, see Table I ). (Table   IV) . When tested at lower concentrations, some of the mAbs were found to be more effective than others (Figure 4 ) and the order of effectiveness for inhibition of growth of HN5 cells was ICR64 (IgGl)>ICR62 (IgG2b) Table IV . They show that growth of the cell lines with high level expression of the EGFR was inhibited by all of the antibodies tested. At a concentration of 156 nM, however, the antibodies were without effect on the growth of SKBR3, SKOV3, EJ or MDA-MB 435 cells.
To investigate if endogenous growth factors present in FCS affected the activity of the anti-EGFR antibodies, experiments were repeated using HN5 cells incubated in media containing 5% or 10% FCS. Only a small shift in baseline (10%) was observed with these antibodies (cf ICR64, Figure 5 ) even at the highest concentration of FCS used and we conclude that at the concentration present in FCS such growth factors had little effect on the growth inhibitory activity of the mAbs. While the head and neck carcinomas HN5, HN6 and HN15 were the most sensitive to antibody induced inhibition of growth, A431 and MDA-MB 468 were less susceptible. A431 cells have been reported to secrete large amounts of a truncated form of the receptor (Weber et al., 1984) and this may have influenced the interaction of the rat antibodies with the transmembrane receptor.
The mAbs bind to the truncated EGFR secreted by A431 cells When '251I-labelled mAbs (2.2-2.5 x I04) were mixed with culture supernatant obtained from A431 cells the binding of antibodies ICR60-64 to EJ cells was abolished (Table V) . Also, the 100 kD truncated receptor was precipitated when cell free supernatants from "5S-methionine labelled A431 cultures were immunoprecipitated with mAbs ICR16 and ICR64 ( Figure 6 ) but not when the control antibodies (ALN/1 1/53, ICR12, ICR55) were used. Clearly, with tumours like A431, the presence of large amounts of truncated receptor may decrease the effective dose of antibody reaching the tumour cells.
Discussion
In this paper we describe the production and some of the properties of six new rat monoclonal antibodies directed against the human EGF receptor. Our results show that these antibodies have the following properties, they: (a) bind with high affinity to two distinct epitopes on the extracellular domain of the human EGFR, (b) do not cross-react with the related product of the c-erbB-2 proto-oncogene, (c) prevent the binding of exogenous growth factors to the receptor, (d) inhibit the growth stimulatory effects of EGF and TGFa on human fibroblasts and (e) inhibit the growth of human tumour cell lines overexpressing this receptor. Three of these antibodies are of the IgG2b isotype (ICR62, epitope C; ICR61, epitope D and ICR65, epitopes C and D) . While all of the antibodies stained frozen sections of cells overexpressing the EGFR, none was found to bind the fully reduced receptor in Western blots nor did they bind to formol-saline fixed paraffin embedded tissues (data not shown). We conclude that mAbs ICR60-64 all recognise conformational determinants on the receptor. During the last decade a number of laboratories have generated antibodies against the human EGFR with a view to their use in structural studies on the receptor or for clinical applications in oncology. In most cases the antibodies were raised in mice against the EGFR on the vulval carcinoma cell line A431. Because the A431 receptor also contains the blood group A antigen, many of the antibodies produced crossreact with this normal antigen limiting their use for diagnostic or therapeutic purposes (see review by Sato et al., 1987) .
As in A43 1 cells, the receptor for the EGFR is overexpressed on the surface of MDA-MB 468 cells but, unlike A431 cells, the gene for the EGFR is not rearranged (Filmus et al., 1987) . Our aim has been to produce rat monoclonal antibodies that bind to different epitopes on the external domain of the human receptor for EGF so that we can identify the best epitope to target for growth inhibition as well as the best antibody for harnessing host immune effector functions. For this reason we have used rats as our source of antibodies rather than mice because some rat antibodies of the IgG2b isotype interact very efficiently with the effector arm of the human immune system (Dyer et al., 1989) .
We have reported (Modjtahedi et al., 1992 ) that rat mAbs raised against the head and neck carcinoma cell line LICR-LON-HN5 bound with high affinity to one of three distinct epitopes (A,B,C) on the EGFR but none were of the IgG2b isotype. Outstanding, in terms of inhibition of growth of HN5 cells, were antibodies ICR 11 and ICR 16 both of which were directed against epitope C. Here we report that two out of a further six mAbs raised against the EGFR on MDA-MB 468 cells also bound to epitope C and one of these was an IgG2b (ICR62) with good growth inhibitory properties in vitro. Interestingly, three of the four other mAbs recognised a new epitope (D) on the EGFR and one of these mAbs (ICR61)iwas an IgG2b. Lastly, antibody ICR65, which is of recent production, is also an IgG2b and this mAb crossreacted with both epitopes C and D. The other properties of this antibody are currently being determined.
The isolation of three antibodies against a novel epitope on the EGFR was surprising since no antibodies of this type were obtained in nine separate fusions when HN5 cells had been used a immunogen. Clearly, this resulted from the use of a different source of EGFR as immunogen (MDA-MB468) which in turn led also to the isolation of three mAbs of the IgG2b isotype. These findings reinforce our view that it is essential to use different source of immunogen to obtain as diverse a population of antibodies (epitope/isotype) from which the best antibody for clinical use can be selected.
In terms of biological activity, antibody ICR61 was the least effective of the new antibodies and complete inhibition of growth of HN5 cells was only obtained at a concentration of 20 nM which was an order of magnitude higher than that required with ICR62 or ICR64, which inhibited completely the growth of these cells at a concentration of 2.4 nM. Indeed ICR64 was one of the best of all the rat mAbs tested and it equalled ICR16 (Modjtahedi et al., 1992) , in terms of its capacity to block the binding of EGF to its receptor and to inhibit the growth of HN5 cells in vitro. We conclude that both epitopes C and D constitute suitable targets for antibody directed therapy.
The antibodies very effectively inhibited the growth in vitro of three different head and neck carcinoma cell lines. They were less effective, however, when tested on A431 or MDA-MB 468 cells. The A431 cell line is aberrant in that it secretes large amounts of a truncated form of the EGFR (Weber et al., 1984) to which all of the rat antibodies bind. This soluble EGFR may therefore reduce the effectiveness of the mAbs at inhibiting growth of this cell line. Furthermore, it has been shown that, in addition to overexpression of the EGFR, both A431 and MDA-MB 468 cells produce TGFax constitutively (Derynck et al., 1987; Ennis et al., 1989) . High level secretion of this ligand by these cells may also reduce the effectiveness of the antibodies in vitro by competing with them for binding to the receptors and this aspect is under investigation.
Currently, we are testing some of the antibodies for their activity in vivo against xenografted human tumours growing in athymic mice and the results obtained are very encouraging. These experiments are described in the accompanying paper and show that ICR62 and ICR64 were effective at eliminating the tumours when given at the time of tumour cell inoculation. ICR62 was also effective in inducing regression of established tumours.
We believe that this new generation of rat mAbs which bind with high affinity to the EGFR, block ligand-receptor interaction and inhibit the growth of squamous cell carcinomas overexpressing the receptor have potential for clinical application. 
